Researcher Spotlight: Reid Merryman, MD Dana-Farber Cancer Institute Marginal zone lymphoma (MZL) is a slow-growing B-cell NHL that has a relatively low number of new diagnoses each year. As a result, few clinical trials are available for MZL patients, including…
Researcher Spotlight: Raghuveer Ranganathan, MD University of North Carolina, Chapel Hill Though CAR T-cell therapy has been successful for many patients with Non-Hodgkin lymphomas, the nature of the two versions currently approved by the FDA can have some severe side…
Researcher Spotlight: Irene Scarfo, PhD Massachusetts General Hospital The majority of chimeric antigen receptor (CAR) T-cell therapies currently being tested in lymphoma, including both therapies that have received U.S. Food and Drug Administration (FDA) approval, target CD19 antigen, and rely…
Researcher Spotlight: Antonia Rotolo, MD, PhD University of Pennsylvania Perelman School of Medicine Researchers are seeking ways to expand the effectiveness of chimeric antigen receptor (CAR) T-cell therapy to lymphoma subtypes for whom the most common type of CAR therapy,…
Researcher Spotlight: Elise A. Chong, MD University of Pennsylvania Perelman School of Medicine Chimeric antigen receptor (CAR) T-cell therapy has been an effective treatment for any patients with B-cell lymphomas who don’t respond to other therapies, producing remissions in 30…